Grant Pickering

CEO Grant Pickering sells 24,461 shares ($1.3M) via scheduled 10b5-1 plan; retains 135,215 shares post-transaction

Grant Pickering, CHIEF EXECUTIVE OFFICER, executed 4 separate sales totaling 24,461 shares (24.5K shares) for $1,284,204.75 ($1.3M) at a blended average price of $52.50 under a pre-arranged 10b5-1 trading plan adopted on 2026-03-03. This scheduled disposition reduced his direct holdings by -15.3% from 159,676 shares to 135,215 shares post-transaction. The sale occurs in an unprofitable company context—net income was $-320,622,000.00 ($-320.6M) over the most recent full fiscal year—and at a stock price -20.9% below the 52-week high of $65.00, though this scheduled trade is not itself subject to timing characterization. His prior open-market sales across all tickers show an average 90-day return of -22.7%, while same-ticker history at PCVX shows five prior sells with 90-day returns ranging from -13.5% to -22.4%, providing context for the broader pattern of sell activity by this insider.

CEO Pickering Grant sold 15,000 PCVX shares for $1.4M blended at $92.45; stock down 15.8% in 30 days, 23.4% from 52-week high.

Pickering Grant, CEO of Vaxcyte, Inc., executed 3 separate sales totaling 15,000 shares for $1,386,794.41 on 2024-12-02, reducing his holdings by 3.2% to 450,301 shares. The company is unprofitable (net income $-103,124,000.00) and the stock has declined 15.8% over 30 days and 23.4% from its 52-week high of $117.93, now at $90.37. His prior sales at PCVX show negative 30-day returns (-13.0%, -11.3%, -12.1%, -4.3%, -5.0%), establishing a pattern of sales preceding near-term weakness, though 90-day outcomes remain unmeasurable for recent trades. The CEO's cross-ticker track record shows an average 30-day return of -6.7% following 20 prior sells, and combined with current price weakness, this sale occurs within a period of sustained stock pressure.

CEO Grant sold 15,000 shares at blended $106.82 for $1.6M on 2024-11-01, retaining 435,219 shares post-sale.

Pickering Grant, CEO of Vaxcyte, executed 3 separate sales totaling 15,000 shares for $1,602,251.52 at prices ranging from $106.35 to $108.50. The sale occurred during a period of elevated valuation: the stock is currently at $106.49, only 9.7% below its 52-week high of $117.93, and up 44.0% over the last 90 days. However, Grant retains substantial holdings of 435,219 shares (a 3.3% reduction), indicating material ongoing exposure to the company. The timing signal is unclear: the company is unprofitable with net income of $-128,703,000 over the most recent fiscal year, yet the stock's 90-day momentum is strongly positive. Prior transactions at this ticker occurred just 25 days earlier (2024-10-07) and their outcomes remain unmeasurable. The cross-ticker track record shows Grant's 20 prior sales achieved a 0.00% well-timed rate at the 90-day mark, meaning none preceded subsequent declines.

CEO Pickering Grant sells 7,098 shares across 8 transactions for $775,154.42 at PCVX on 2024-10-07

CEO Pickering Grant executed 8 separate sales totaling 7,098 shares for $775,154.42 on 2024-10-07, reducing holdings by 4.9% from 145.7K shares to 138.6K shares. The sales occurred near the 52-week high (current price $111.75 is -4.6% from the $117.12 peak), with a blended average price of $109.21. Notably, Grant sold again just 6 days after 4 prior sales on 2024-10-01, reflecting repeated open-market dispositions in a compressed timeframe. The company reported a net loss of $128.7M over its most recent full fiscal year, indicating ongoing unprofitability despite a market cap of $12.5B. While his cross-ticker track record shows an average 90-day return of +33.0% after prior sales (poorly-timed selling across other holdings), near-term price action and the sequential nature of these sales warrant close monitoring for any broader strategic or financial signals.

CEO Pickering Grant sold 55,000 shares for $6.3M at $114.25 avg in 9 transactions on 2024-10-01

Pickering Grant executed 9 separate sales totaling 55,000 shares for $6,283,860.79 at a blended average price of $114.25, reducing his holdings by 10.9% to 450,219 shares. The sale occurred at a price near the company's 52-week high of $117.12 (within 2.7% of peak), and the stock has gained 42.8% over 90 days. Against his cross-ticker track record of 20 prior sells with a 50.00% well-timed rate and average 90d return of +11.0%, the immediate context shows mixed timing signals: his prior 5 trades at PCVX achieved strong 30-day returns in August (+46.4%, +45.3%) but showed net negative timing at the 90-day mark (0 of 1 prior sells well-timed). The company is unprofitable with a net loss of $128,703,000.00 against a $12.4B market cap, adding uncertainty to the fundamental backdrop. The sale's size and timing near multi-month highs merit monitoring of whether the transaction reflects disclosure requirements (e.g., under a 10b5-1 plan) or discretionary decisions by the CEO.

Vaxcyte CEO Grant Pickering sold 15,000 shares (15.0K shares) for $1,184,766.71 on 2024-08-23 at blended $78.98

Grant Pickering, Vaxcyte's CEO, executed two separate sales totaling 15,000 shares (15.0K shares) for $1,184,766.71 on 2024-08-23, reducing his holdings by 3.0% to 478,888 shares (478.9K shares). The company is unprofitable with a net loss of $128,703,000.00 and trades at $79.48 today, 6.7% below its 52-week high, having declined 5.4% over the prior 30 days despite a 15.7% rally over 90 days. His prior five trades at Vaxcyte show mixed timing outcomes on measurable 30-day windows: three sales posted gains (+13.0%, +10.9%, +11.8%) while two posted losses (-7.6%, -6.8%), and across all his open-market activity, his sells have achieved a 60.00% well-timed rate over 90 days. The current filing occurs near the company's 52-week peak in a volatile trading environment, and investors should monitor whether this sale precedes material developments at the unprofitable biotech.

CEO Grant sold 15,000 PCVX shares for $1.3M on 2024-07-23; stock up 12.4% in 30 days post-sale.

CEO Pickering Grant executed 2 separate sales totaling 15,000 shares for $1,263,911.69 at a blended average price of $84.26, reducing his holdings by 3.0% to 478,888 shares. The company remains unprofitable with negative net income of $-95,020,000.00, yet the stock has appreciated 12.4% over the 30 days following this transaction and now trades at $85.16, approaching its 52-week high. At the ticker-specific level, Grant's 5 prior PCVX trades over the past two months each showed strong 30-day gains (ranging 7.3% to 13.0%), but none have reached 90-day measurable outcomes; his cross-ticker historical 90-day well-timed rate stands at 60.00%, indicating mixed execution timing across his broader trading history. The recent sale occurs in a period of significant upward momentum, and the company's ongoing unprofitability is a material baseline context for evaluating this insider activity.

CEO Pickering Grant sold 15,000 PCVX shares (3 transactions) for $1,134,579.44 at $75.64 avg; stock now at $74.50 amid unprofitability.

Pickering Grant, CEO of Vaxcyte Inc., executed 3 separate sales totaling 15,000 shares for $1,134,579.44 on 2024-06-24, reducing holdings by -3.0% to 478,888 shares. The blended average price of $75.64 sits slightly above the current price of $74.50, and within the 52-week range. Notably, PCVX remains deeply unprofitable with net income of $-95,020,000.00, and the CEO's prior sales at this ticker show a timing pattern of 0 of 2 measured outcomes achieving negative 90-day returns; his cross-ticker track record shows 20 prior sells with a 52.94% well-timed rate. The filing itself carries no discretionary signal of strategic intent—it is a factual record of executed sales at specified prices during a period when the company's fundamentals remain negative.